Company: ATRA
Filing Date: 2025-03-07
Form Type: 10-K
Source: 0000950170-25-035507
Chunk: 120

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-03-07
Form: 10-K
Item: Item 1A
Chunk 120
---
 have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position.

Enforcing a claim that a third party illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, the laws of certain foreign countries do not protect proprietary rights such as trade secrets to the same extent or in the same manner as the laws of the U.S. Misappropriation or unauthorized disclosure of our trade secrets to third parties could impair our competitive advantage in the market and could materially adversely affect our business, results of operations and financial condition. 

Risks Related to Commercialization of Our Product and Product Candidates

Our commercial success depends upon developing a clearly differentiated product and attaining significant market acceptance of our product and product candidates, if approved, among physicians, patients, healthcare payors and the medical community, including hospitals and outpatient clinics.

Even if we or our partners obtain regulatory approval for any of our product candidates that we may develop or acquire in the future, the product may not gain market acceptance among physicians, healthcare payors, patients or the medical community that supports our product development efforts, including hospitals and outpatient clinics. Market acceptance of any of our product and product candidates for which we receive approval depends on a number of factors, including:

•the efficacy and safety of the product candidates as demonstrated in clinical studies;

•the clinical indications and patient populations for which the product candidate is approved; 

•the inclusion into clinical treatment guidelines; 

•acceptance by physicians and patients of the drug as a safe and effective treatment;

•the administrative and logistical burden of treating patients;

•the differentiation profile versus other approved therapies at the time of commercialization;

•the ability to identify in a timely manner the appropriate patients who will benefit from specific therapy;

•the consideration of novel cellular therapies by physicians, hospitals and third party payors;

•the potential and perceived advantages of product candidates over alternative treatments;

•the safety of product candidates seen in a broader patient group, including its use outside the approved indications;

•any restrictions on use together with other medications;

•the prevalence and severity of any side effects;

•product labeling or product insert requirements of the FDA or other regulatory authorities;

60

•the geography and timing of market introduction of our products as well as competitive products;

•the development of manufacturing and distribution processes for our product and product candidates;

•the cost of treatment in relation to alternative treatments;

•the availability of coverage and adequate reimbursement from, and our commercialization